A phase II randomised study of preoperative trastuzumab alone or combined with everolimus in patients with early HER2-positive breast cancer and predictive biomarkers (RADHER trial).
Saved in:
| Title: | A phase II randomised study of preoperative trastuzumab alone or combined with everolimus in patients with early HER2-positive breast cancer and predictive biomarkers (RADHER trial). |
|---|---|
| Authors: | Campone, Mario1 (AUTHOR), Bachelot, Thomas2 (AUTHOR), Treilleux, Isabelle3 (AUTHOR), Pistilli, Barbara4 (AUTHOR), Salleron, Julia5 (AUTHOR), Seegers, Valérie6 (AUTHOR), Arnedos, Monica4 (AUTHOR), Loussouarn, Delphine7 (AUTHOR), Wang, Qing8 (AUTHOR), Vanlemmens, Laurence9 (AUTHOR), Jimenez, Marta10 (AUTHOR), Rios, Maria11 (AUTHOR), Diéras, Véronique12 (AUTHOR), Leroux, Agnès13 (AUTHOR), Paintaud, Gilles14 (AUTHOR), Rezai, Keyvan15 (AUTHOR), André, Fabrice4 (AUTHOR), Lion, Maëva13 (AUTHOR), Merlin, Jean-Louis1,13 (AUTHOR) jl.merlin@nancy.unicancer.fr |
| Source: | European Journal of Cancer. Nov2021, Vol. 158, p169-180. 12p. |
| Database: | Academic Search Ultimate |
Be the first to leave a comment!
